Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

21. Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Relapse risk after discontinuation of risperidone in Alzheimer's disease. 23075176 2012 10 18 2012 10 23 2016 12 15 1533-4406 367 16 2012 Oct 18 The New England journal of medicine N. Engl. J. Med. Relapse risk after discontinuation of risperidone in Alzheimer's disease. 1497-507 10.1056/NEJMoa1114058 Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation (...) of the medication has not been established. Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse

NEJM2012 Full Text: Link to full Text with Trip Pro

22. Paliperidone palmitate (Xeplion) - maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone

Paliperidone palmitate (Xeplion) - maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone

Scottish Medicines Consortium2011

24. Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking

Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking Article Text Therapeutics Review: clozapine shows some improved

Evidence-Based Mental Health2011

25. Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline

Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline | Evidence (...) -generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Article Text Therapeutics Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Statistics from

Evidence-Based Mental Health2011

26. Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

Long-acting risperidone and oral antipsychotics in unstable schizophrenia. 21366475 2011 03 03 2011 03 08 2013 11 21 1533-4406 364 9 2011 Mar 03 The New England journal of medicine N. Engl. J. Med. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. 842-51 10.1056/NEJMoa1005987 Long-acting injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment and outcomes in schizophrenia, but it has not been tested in a long-term randomized (...) trial involving patients with unstable disease. We randomly assigned patients in the Veterans Affairs (VA) system who had schizophrenia or schizoaffective disorder and who had been hospitalized within the previous 2 years or were at imminent risk for hospitalization to 25 to 50 mg of long-acting injectable risperidone every two weeks or to a psychiatrist's choice of an oral antipsychotic. All patients were followed for up to 2 years. The primary end point was hospitalization in a VA or non-VA

NEJM2011

27. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.

Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. 21813427 2011 08 04 2011 08 05 2016 10 17 1538-3598 306 5 2011 Aug 03 JAMA JAMA Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. 493-502 10.1001/jama.2011.1080 Serotonin reuptake-inhibiting (SRI) antidepressants are the only FDA-approved pharmacotherapies for the treatment (...) of posttraumatic stress disorder (PTSD). To determine efficacy of the second-generation antipsychotic risperidone as an adjunct to ongoing pharmacologic and psychosocial treatments for veterans with chronic military-related PTSD. A 6-month, randomized, double-blind, placebo-controlled multicenter trial conducted between February 2007 and February 2010 at 23 Veterans Administration outpatient medical centers. Of the 367 patients screened, 296 were diagnosed with military-related PTSD and had ongoing symptoms

JAMA2011

28. Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial

Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial 19786416 2009 11 02 2010 11 15 2013 11 21 1477-0873 23 11 2009 Nov Clinical rehabilitation Clin Rehabil Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial. 963-72 10.1177/0269215508101743 To evaluate the quality of life, efficacy and safety of Warm (...) -Supplementing Kidney Yang (WSKY) added to risperidone in patients with schizophrenia. A randomized controlled trial. The outpatient and inpatient departments of three hospitals. One hundred and twenty patients with clinically diagnosed schizophrenia with predominantly negative symptoms were included in the study. All 120 patients were randomly assigned to double-blind treatment with WSKY group (n = 60) or placebo group (n = 60) added to risperidone for eight weeks. The efficacy measures included the World

EvidenceUpdates2010

29. Review: Is aripiprazole as effective as risperidone in people with schizophrenia?

Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Review: Is aripiprazole as effective as risperidone in people with schizophrenia? | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Article Text Therapeutics Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Statistics from Altmetric.com No Altmetric data available for this article. Question Question: What are the effects of aripiprazole compared

Evidence-Based Mental Health2010

30. Review: lack of evidence for the optimal dose of risperidone for schizophrenia

Review: lack of evidence for the optimal dose of risperidone for schizophrenia Review: lack of evidence for the optimal dose of risperidone for schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lack of evidence for the optimal dose of risperidone for schizophrenia Article Text Therapeutics Review: lack of evidence for the optimal dose of risperidone for schizophrenia Statistics from Altmetric.com No Altmetric data available for this article. Question Question: What is the most effective dose of risperidone for treating

Evidence-Based Mental Health2010

31. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities.

Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is increasingly recognised as occurring in people with intellectual disability (ID), although treatment of ADHD in this population has not ben tested widely. Risperidone has been used to treat ADHD in people with ID, although the evidence for its effectiveness is unclear. OBJECTIVES: To examine the effectiveness of risperidone (...) of review articles were examined and citation searches were performed in ISI Web of Knowledge. SELECTION CRITERIA: All randomised controlled trials (RCTs), both published and unpublished, in any language, in which children or adults with ADHD and ID were treated with risperidone. DATA COLLECTION AND ANALYSIS: Data collection and analyses were planned but not performed due to a lack of suitable studies. MAIN RESULTS: Eleven studies were considered but none were suitable for inclusion. AUTHORS

Cochrane2009

32. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China

Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of first-line treatment with long-acting risperidone, olanzapine, or quetiapine for young patients with schizophrenia. The authors concluded that risperidone was cost

NHS Economic Evaluation Database.2009

33. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss Treur M, Heeg B, Moller HJ, Schmeding A, van Hout B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of branded versus generic risperidone, for patients with schizophrenia, assuming different losses in compliance after generic substitution. Assuming the price of the generic substitute was 40% below

NHS Economic Evaluation Database.2009

34. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Article Text Therapeutics Haloperidol, olanzapine and risperidone reduce

Evidence-Based Mental Health2008

35. Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects

Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects Article Text Therapeutics Haloperidol, risperidone and olanzapine are similarly effective

Evidence-Based Mental Health2008

36. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia

A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia 18480682 2008 05 15 2008 09 11 2013 11 21 0271-0749 28 3 2008 Jun Journal of clinical psychopharmacology J Clin Psychopharmacol A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. 264-370 10.1097/JCP.0b013e318172473c Hyperprolactinemia is a common (...) adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation. Empirical evidence has shown that some herbal medicines have suppressive effects on prolactin (PRL) hyperactivities. This study was designed to compare the herbal preparation called Peony-Glycyrrhiza Decoction (PGD) with bromocriptine (BMT), a dopamine agonist widely used for PRL-secreting disorders, in the treatment of risperidone-induced hyperprolactinemia. Twenty schizophrenic women who were

EvidenceUpdates2008

37. Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia

Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Article Text Therapeutics Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any

Evidence-Based Mental Health2008

38. Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia

Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia Article Text Therapeutics Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2008

39. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials

The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis (...) identified articles and reviews were also searched. Study selection Eligible for inclusion in the review were randomised controlled trials (RCTs) that compared atypical antipsychotics (clozapine, olanzapine, risperidone, ziprasidone, quetiapine, aripiprazole, amisulpride) with placebo for the treatment of post-traumatic stress disorder (PTSD), either as a monotherapy or add-on therapy. There were no restrictions on duration of treatment, comorbidities, concomitant medications, presence of psychotic

DARE.2008

40. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Heeg B M, Antunes J, Figueira M L, Jara J M, Marques Teixeira J, Palha A P, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout B A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of long-acting risperidone (LAR) as first-line treatment of schizophrenia compared with conventional haloperidol depot and oral risperidone. The authors concluded that treatment with LAR might be cost

NHS Economic Evaluation Database.2008